| INTRODUC TI ON
Osteosarcoma is the most common nonhematological malignancy of bone in children aged 15-19 years and typically arises around the growth plate of long bones, with highly aggressive and early systemic metastases. 1 With surgical advances and the development of dose-intensive, multiagent chemotherapy, the 5-year overall survival rate for osteosarcoma has increased to approximately 50-70%. 1, 2 Despite clinical and therapeutic improvements, patients with metastatic or recurrent disease have a poor prognosis, with a 5-year overall survival rate of approximately 20% in the past three decades. 1, 3 Therefore, novel therapeutic approaches with a lower working dose and improved targeting are urgently needed.
Raddeanin A (RA) is an active oleanane-type triterpenoid saponin extracted from a commonly used traditional Chinese medicinal herb,
Anemone raddeana Regel, which exerts antitumor activity through inhibiting proliferation and angiogenesis and inducing apoptosis in multiple cancer cell types, such as human colorectal cells, gastric cancer cells, and human hepatocellular carcinoma cells. [4] [5] [6] [7] RA mainly functions to reduce inflammation and tumor activity. Furthermore, recent research has shown that RA can suppress the progression of human colorectal carcinoma. [4] [5] [6] [7] However, the effects of RA on human osteosarcoma cells are unknown.
Reactive oxygen species (ROS) function as second messengers in signal transduction and gene regulation in a variety of cell types and under several biological conditions, such as in the presence of cytokines, growth factors, and hormone treatments, and are involved in ion transport, transcription, neuromodulation, and apoptosis. 8, 9 As a heterogeneous group of diatomic oxygen molecules from free and nonfree radical species, ROS trigger apoptosis by causing various cellular stresses and regulate several apoptotic effectors, such as caspases, Bcl-2, and cytochrome c. 8 Broadly speaking, ROS are capable of activating p38 MAPK, JNK, ERK, and Akt pathways, depending on the context. 8, [10] [11] [12] Jun amino-terminal kinase, a stress-activated protein kinase of the MAPK family, regulates a variety of cellular events, including autophagy and apoptosis, which are complex events depending on cell type, nature of the death stimulus and activity of other signaling pathways. 13 A major target of the JNK signaling pathway is the activator protein-1 (AP-1) transcription factor, which is activated in part by the phosphorylation of c-Jun and related molecules. 9, 10, 14, 15 Some reports have indicated that there is an interaction between a region within c-Jun and specific sites within signal transducer and activator of transcription 3 (STAT3) in vitro and in vivo. [16] [17] [18] [19] Additionally, JNK is an upstream kinase responsible for the phosphorylation of STAT3, 16, [20] [21] [22] and both are known to play critical roles in the regulation of apoptosis signal transduction in cancer.
Signal transducer and activator of transcription 3 is one of the six members of a family of transcription factors that regulates gene expression related to the cell cycle, cell survival, and the immune response. 23 Compared with the transient activation of STAT3 in normal cells, STAT3 remains abnormally active in tumors and promotes the induction and survival of cancer. 24 Our previous results showed that selective inactivation of STAT3 blocks tumorigenesis in human osteosarcoma. [25] [26] [27] In the present study, we investigated the antitumor activity of RA on human osteosarcoma and explored the possible mechanisms of RA induction. We found that RA induces apoptosis in human osteosarcoma cells by modulating ROS-dependent JNK/c-Jun and STAT3 signaling pathways. Collectively, we
show the effects of RA in human osteosarcoma and its possible mechanisms.
| MATERIAL S AND ME THODS

| Cells and cell culture
Human osteosarcoma cell lines 143B and SJSA were obtained from ATCC (Manassas, VA, USA). The cells were cultured in high-glucose DMEM (Cyclone, Logan, UT, USA) with 10% FBS (Thermo Fisher Scientific, Waltham, MA, USA), 100 U/mL penicillin and 100 μg/mL streptomycin (Thermo Fisher Scientific) at 37°C in an atmosphere of 5% CO 2 . 
| Materials and chemicals
| Cell viability assay
Cell proliferation was measured using the CCK-8 assay (Dojindo, Kumamoto, Japan). Briefly, cells were subcultured in a 96-well plate at a density of 5 × 10 3 cells/mL and incubated overnight and then treated with various concentrations of RA with or without GSH or SP600125. After 24 or 48 hours of incubation, the cells were incubated with CCK-8 working solution for 1 hour at 37°C following the manufacturer's protocol. The resulting absorbance at 450 nm was measured using a microplate reader iMark (Molecular Devices, Sunnyvale, CA, USA). 
| Clone formation assay
| Flow cytometric analysis of apoptosis
Osteosarcoma cell lines were seeded in six-well plates at a density 
| JNK knockdown in human osteosarcoma cell lines
Four JNK-targeted shRNA sequences were designed under the guidelines of the WI siRNA Selection Program (http://sirna.wi.mit.edu/).
The JNK-shRNA sequence was 5′-CCTGAAACGATATCAGAATTT-3′; the control sequence was 5′-CAACAAGATGAAGAGCACCAA-3′, and the shRNA vector was pLKO.1. The protocol for the construction of JNK-shRNA lentiviruses was as previously described. 28 The plasmids were carefully transfected into 293T cells. After 48 hours of transfection, the supernatant was harvested and filtered using a 0.45-μm filter. The same procedure was used to construct the empty lentiviral vector as the control group. Stable JNK-shRNA-transfected cells were screened with 2 μg/mL puromycin to improve transfection efficiency.
| siRNA-mediated STAT3 knockdown
Cells were seeded in a six-well plate. After 24 hours, siRNA duplex targeting STAT3 was transfected using Lipofectamine 2000 (Invitrogen Life Technologies, Los Gatos, CA, USA) according to the instructions.
The siRNA-STAT3 sequence was 5′-CGTCATTAGCAGAATCTCA-3′. 
| Animal model
| TUNEL assay
Apoptosis in tumor samples was identified using a TUNEL Assay Kit (Beyotime) according to the manufacturer's instructions. Briefly, paraffin-embedded slides were deparaffinized in xylene, rehydrated in gradient ethanol and incubated in proteinase K for antigen retrieval.
After washing with PBS three times, the sections were stained with TUNEL detection mixture for 1 hour at 37°C in a humidified chamber. The cell nuclei were stained with DAPI (Beyotime). Apoptotic tumor cells in randomly chosen fields on the slides were observed using a fluorescence microscope (Leica, Wetzler, Germany).
| Statistical analysis
All data are presented as the mean ± SD from at least three independent experiments. Fisher's exact test, unpaired Student's t test, and one-way ANOVA were used to compare differences between the control and treatment groups. All statistical analyses were carried out using SPSS version 18.0 software (IBM Corporation, Chicago, IL, USA). P-values <0.05 (*) and <0.01 (**) were considered significant.
| RE SULTS
| Raddeanin A activates ROS generation in human osteosarcoma cells
Reactive oxygen species are important regulators in various pathways, including apoptosis, and they promote sustained JNK activation. 8 Mitochondria are the major intracellular source of ROS. 8, 13, [29] [30] [31] [32] [33] [34] Glutathione is present in the cells in both reduced (GSH) and oxidized (GSSG) states, and the harmful effect of ROS is counterbalanced by antioxidants such as GSH. To investigate whether ROS levels were increased because of RA treatment, DCFH-DA was used in a fluorescence microplate experiment. As shown in Figure 1A , cells treated with RA showed a dramatic enhancement in the DCFH-DA fluorescence signal compared with control cells, where ROS were scavenged by the antioxidant GSH. Consistent with the microscopic data, as shown in Figure 1B , the DCFH-DA flow cytometry assay showed increased ROS levels in cells treated with RA, and this increase could be strongly inhibited by GSH. For example, ROS production resulting from treatment with 2 μmol/L RA for 12 hours was 1000-fold higher ( Figure 1C) than that of the blank control, whereas the same ROS level was sixfold higher ( Figure 1C ) than that after pretreatment with 1.5 mmol/L GSH F I G U R E 1 Raddeanin A (RA) induced intracellular reactive oxygen species (ROS) generation. A, Human osteosarcoma cells were preincubated with glutathione (GSH) for 2 h and then treated with 2 μmol/L RA for 24 h. Cells were stained with 2′-7′-dichlorodihydrofluorescein diacetate (DCFH-DA) at 37°C in the dark for 30 min, and ROS levels were determined by fluorescence microscopy. Scale bar, 50 μm. B, Cells were stained with DCFH-DA, and ROS levels were determined by flow cytometry. C, Mean fluorescent intensity is shown as histograms. Data are presented as the means ± SD (n = 3). *P < 0.05, **P < 0.01, significantly different compared with the untreated control group for 2 hours, which confirmed the efficacy of GSH pretreatment. These results show that GSH significantly attenuates ROS induction and that RA activates ROS generation in human osteosarcoma cells.
| Raddeanin A inhibits cell proliferation and induces apoptosis by ROS generation
To investigate the antiproliferative activity of RA, 143B and SJSA were treated with RA for 48 hours, and cell viability was then measured by CCK-8 assays (Figure 2A ). After RA treatment, cell viability was significantly decreased in a dose-dependent method. RA treatment also reduced the number of colonies, as determined using a clone formation assay ( Figure 2B,C) . Importantly, GSH pretreatment alleviated RA cytotoxicity, as demonstrated by recovery of both clone formation ( Figure 2B ) and cell viability (Figure 2A ) in GSH-pretreated samples. Clone formation rate increased from approximately 30% (29.97 ± 5.20) to approximately 50% (49.31 ± 5.47) with GSH pretreatment, which was a significant difference. These results show that GSH partially rescued osteosarcoma cells from ROS damage stemming from RA treatment, confirming that RA cytotoxicity was mediated by ROS generation.
To quantify cell apoptosis, we used Annexin V-FITC/propidium iodide (PI) double staining. The results showed that the treatment of osteosarcoma cells with RA resulted in an increase in both early and late apoptotic cells ( Figure 3A ). Following pretreatment with 1.5 mmol/L GSH for 2 hours, the percentage of apoptotic cells was significantly reduced, as determined by flow cytometric analysis of apoptosis ( Figure 3A ).
We also investigated the expression of important signaling proteins involved in DNA repair and apoptosis by western blotting. As shown in Figure 3C , protein expression levels of cleaved PARP, cleaved caspase-8, cleaved caspase-9, cleaved caspase-3, and Bax were all remarkably increased, and the protein expression levels of the antiapoptotic proteins 
| Raddeanin A activates the JNK/c-Jun signaling pathway dependent on ROS production
To evaluate the molecular mechanism of the antitumor activity of RA in osteosarcoma, activation of cell signaling molecules was ROS generation is an early event in apoptosis and directly relates to caspase and MAPK activation, especially JNK signaling pathway activation. 8, 15 We investigated whether ROS generated by RA induced apoptosis through JNK signal transduction. 143B and SJSA cells were subjected to pretreatment with the ROS scavenger GSH at 1.5 mmol/L for 2 hours, followed by RA treatment. Expression of phosphorylated JNK and cJun was measured by western blot analysis. RA-induced JNK and c-Jun phosphorylation was obviously inhibited by pretreatment with GSH, suggesting that RA-induced ROS-mediated osteosarcoma cell apoptosis is JNK dependent ( Figure 4C ). In addition, increased expression of cleaved PARP induced by RA was attenuated in osteosarcoma cells pretreated with GSH ( Figure 4D ). The Erk1/2 inhibitor LY3214996 was used to assess the effect of Erk1/2 on osteosarcoma cells after RA treatment as shown in Figure 4E ,F and G. The inhibitor inhibited RA-induced apoptosis in osteosarcoma ( Figure 4E,G) . Interestingly, LY3214996 also inhibited JNK expression and marginally increased phospho-STAT3 S727 ( Figure 4F ). These results suggest that ROS generated by RA trigger JNK-and c-Jun-mediated osteosarcoma cell apoptosis.
| Raddeanin A induces apoptosis by the JNK/ c-Jun pathway in human osteosarcoma cells
To further investigate the molecular mechanism by which RA induces apoptosis in human osteosarcoma, we used the specific JNK inhibitor SP600125 ( Figure 5A ) and shRNA targeting JNK ( Figure 5B ,E). As shown in Figure 5A and E, the expression of phospho-c-Jun and total c-Jun was remarkably downregulated in SP600125-treated cells. 
| Raddeanin A-induced JNK pathway activation inhibits STAT3 phosphorylation
Our team previously reported that STAT3 is a critical regulator of osteosarcoma development and progression. [25] [26] [27] The effect of RA on the JNK and STAT3 signaling pathways was assessed to investigate the molecular mechanism of the antitumor activity of RA using pharmacological inhibitors and shRNA. As shown in Figure 6A , SP600125 partly rescued the RA-induced inhibition of phospho-STAT3 ( Figure 6H ). Taken together, these results indicate that RAinduced activation of the JNK pathway inhibits phospho-STAT3 in human osteosarcoma cells.
| Raddeanin A inhibits tumor growth and induces apoptosis in osteosarcoma xenografts
To determine whether RA inhibits osteosarcoma growth and induces apoptosis in vivo, we established osteosarcoma xenografts in the medullary cavity of tibia for each mouse injected with 143B.
When the tumors were established, the mice were injected with either vehicle (DMSO) or RA every 3 days. As shown in Figure 7A , RA given at 5 or 10 mg/kg significantly inhibited tumor growth, and tumor weights were markedly reduced in the RA-injection groups compared with the vehicle group. In Figure 7B , RA treatment at 5 and 10 mg/kg resulted in significant decreases in the weights of the tumor-bearing leg by 33.8% and 58%, respectively, after eight doses.
Moreover, we detected apoptotic cells in osteosarcoma tissue sections using the TUNEL assay. As shown in Figure 7C Taken together, these data showed that RA inhibits tumor growth and promotes the apoptosis of osteosarcoma cells in a preclinical osteosarcoma xenograft model.
| D ISCUSS I ON
In the present study, we investigated the antiproliferative and apoptotic effects of RA on human osteosarcoma cell lines. We found that RA significantly reduced cell proliferation, blocked clone for- The effects of natural compounds on the inhibition of osteosarcoma have previously been reported by our research team. [25] [26] [27] 36 For instance, we found that pectolinarigenin significantly suppressed osteosarcoma cell proliferation, induced apoptosis and inhibited migration and invasion in osteosarcoma cells. 26 Alternol, a novel compound purified from microbial fermentation products, not only inhibited osteosarcoma cell proliferation and migration and induced caspase-dependent apoptosis and G2/M cell cycle arrest in vitro, but also suppressed tumor growth in an orthotopic tibial osteosarcoma model. 27 In addition, our team has demonstrated that two natural compounds, toosendanin and erianin, suppress human osteosarcoma growth and metastasis. 25, 36 The results of the present re- In conclusion, our research shows that RA has the potential to inhibit osteosarcoma growth by JNK/c-Jun activation and STAT3 inhibition and to induce osteosarcoma apoptosis in a mouse primary tibia model. Therefore, RA is a potential bioactive compound for treating osteosarcoma and could be used as a potent clinically therapeutic agent. However, it is possible that RA exerts its activity against osteosarcoma by impairing/activating other signaling pathways. To understand the function of RA in osteosarcoma, the molecular mechanism requires comprehensive investigation. 
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